Quintrio
Home

SERVICES-MEDICAL LABORATORIES

BioNexus Gene Lab Corp Common stock

BGLC

BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $0.66 – $0.825
Volume 13,156
Market cap $2M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$2.41M
Price / earnings
—
Price / book
0.31×
Price / sales
0.77×
EV / sales
0.39×
EV / EBITDA
-0.45×

Profitability

Earnings per share
-$0.88
Return on assets
-29.51%
Return on equity
-33.11%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.01×
Current ratio
6.08×
Quick ratio
5.28×
Cash ratio
1.52×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$853.6K

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for BGLC, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$76.16K$22.84K$483.76K$2.54M$2.26M$2.14M$2.52M$2.63M
Cost of revenue$63.17K$23.63K$487.74K$2.17M$1.89M$1.79M$2.21M$2.3M
Gross profit$12.98K-$790-$3.98K$377.69K$368.02K$343.49K$309.23K$326.54K
Selling, general and administrative$334.55K$380.4K$1.01M$997.26K$1.13M$932.57K$801.8K$2.04M
Research and development$13.67K$14.49K$11.1K$14.88K$12.56K$12.14K$17.4K$10.44K
Total operating expenses$416.38K$570.64K$1.08M$1.19M$1.14M$959.68K$1.58M$2.05M
Operating income-$403.4K-$571.43K-$1.08M-$810.27K-$769.75K-$616.19K-$1.27M-$1.72M
Interest expense-$4.06K-$3.09K-$3.27K-$6.48K-$4.88K-$4.91K-$5.81K-$6.19K
Income before taxes-$286.45K-$543.58K-$1.04M-$708.99K-$616.17K-$623.33K-$422.03K-$1.34M
Income taxes$0$0$0$0$0$0-$73.71K$1.56K
Net income-$286.45K-$543.58K-$1.04M-$708.99K-$616.17K-$623.33K-$348.32K-$1.35M
Net income attributable to common shareholders-$286.45K-$543.58K-$1.04M-$708.99K-$616.17K-$623.33K-$348.32K-$1.35M
EBITDA-$375.34K-$543.14K-$1.05M-$781.27K-$741.95K-$589.55K-$1.24M-$1.69M
Basic earnings per share-$0.12-$0.23-$0.51-$0.40-$0.34-$0.35-$0.01-$0.75
Diluted earnings per share-$0.12-$0.23-$0.51-$0.40-$0.34-$0.35-$0.01-$0.75

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

RYET to Enter Malaysian Healthcare Through Exclusive Cogni AI License to BioNexus Gene Lab

Ruanyun Edai Technology Inc. (NASDAQ: RYET) has signed a definitive agreement to grant BioNexus Gene Lab Corp. (NASDAQ: BGLC) an exclusive 10-20 year license for its Cogni AI document-intelligence platform in Malaysian healthcare. RYET will receive 560,000 BGLC shares and a 10% royalty on qualifying technology receipts. The deal aligns with Malaysia's RM1 billion healthcare digitalization initiative, though neither company has secured government contracts yet.

GlobeNewswire Inc.

BioNexus Gene Lab Corp. Files 2024 Annual Report Highlighting Strategic Innovation, Operational Resilience, and Growth Trajectory

BioNexus Gene Lab Corp. (BGLC) filed its 2024 annual report, showcasing strategic realignment, technological advancement, and improved financial performance. The company highlighted its blockchain-native treasury strategy, expansion of genomic diagnostics offerings, and partnerships to scale its AI-based health diagnostics initiatives.

GlobeNewswire Inc.

BioNexus Gene Lab Corp. Bersetuju untuk Melabur RM 1.2 juta dalam Ascension Innovation (AISB) untuk Memajukan Inovasi Kesihatan Digital menerusi penerimaan AI dalam Penjagaan Kesihatan

KUALA LUMPUR, Malaysia, April 20, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corporation (NASDAQ: BGLC), peneraju global dalam diagnostik genomik dan teknologi penjagaan kesihatan, mengumumkan pelaburan strategik melalui anak syarikat milik penuh mereka, MRNA Scientific Sdn Bhd, dalam Ascension Innovation Sdn Bhd (AISB), sebuah syarikat persendirian di Malaysia. Pelaburan ini menegaskan komitmen BGLC dalam memajukan penyelesaian penjagaan kesihatan menerusi AI dan analisis ramalan termaju.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Apr 7, 20251-for-10reverse split
Jul 20, 20231-for-12reverse split